TidalSense, a Cambridge-based company specializing in AI-driven respiratory diagnostics, has secured €16.6 million ($19 million) in funding to enhance its commercial efforts in the UK and expand globally, particularly into the USA. This latest investment round included contributions from Cross-Border Impact Ventures and returning investors like BGF and Airstream Capital, bringing the company’s total funding to €35.1 million ($40 million), which includes significant grants from various UK health organizations.
Founded in 2013, TidalSense aims to address the pressing need for improved respiratory diagnostics, particularly for chronic obstructive pulmonary disease (COPD), which affects a significant portion of the population yet remains underprioritized in healthcare discussions. The company's innovative diagnostic tool, N-Tidal Diagnose, requires a simple 75-second breath test using a handheld device, significantly reducing the complexity and time associated with traditional spirometry tests. This technology is designed to be accessible, allowing any trained healthcare professional to administer the test without specialized qualifications.
The N-Tidal Diagnose has shown promising results, achieving over 90% diagnostic accuracy in initial validations. With the World Health Organization now recognizing COPD as a global health priority, TidalSense's approach could revolutionize how respiratory diseases are diagnosed and treated, particularly in lower-income and minority communities that often face barriers to care.
As TidalSense prepares for its US market entry, the company has strengthened its leadership team, bringing in experienced professionals to support its mission. This expansion not only aims to improve access to timely diagnostics but also hopes to reshape perceptions around respiratory diseases, highlighting the impact of environmental factors alongside traditional risk factors like smoking. The ongoing evolution of TidalSense's technology and its commitment to addressing healthcare disparities position it as a key player in the future of respiratory health diagnostics.